文献速递类风湿关节炎脊柱关节炎

甲氨蝶呤治疗阻碍免疫介导炎症性疾病患者疫苗特异性CD4 T细胞应答的诱导

Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.
PubMed 文献 · RMD Open · 2024-10-07

研究纳入18例接受甲氨蝶呤单药治疗的类风湿关节炎患者、2例银屑病关节炎患者、10例未接受免疫抑制治疗的类风湿关节炎患者及29名健康对照,分析两剂SARS-CoV-2 mRNA疫苗接种后7天和3-6个月的B细胞与CD4 T细胞应答。结果显示甲氨蝶呤治疗患者抗原特异性CD4 T细胞频率降低,且与抗RBD IgG抗体强相关,提示CD4 T细胞活性下降可能导致抗体应答减慢。

要点

  • 甲氨蝶呤治疗患者接种两剂SARS-CoV-2疫苗后7天,抗原特异性CD4 T细胞频率降低。
  • 该CD4 T细胞频率与抗RBD IgG抗体强相关。
  • 甲氨蝶呤治疗患者总B细胞和T细胞计数及刺突特异性B细胞频率与对照相似。

核心结论

  • 甲氨蝶呤治疗降低疫苗诱导的CD4 T细胞活化,并与较低的抗体应答相关。

研究设计与样本

  • 研究纳入18例接受甲氨蝶呤单药治疗的类风湿关节炎患者、2例接受甲氨蝶呤单药治疗的银屑病关节炎患者、10例未接受免疫抑制治疗的类风湿关节炎患者及29名健康对照。
  • 在两剂SARS-CoV-2 mRNA疫苗接种后7天和3-6个月分析CD4 T细胞和B细胞应答,采用高维流式细胞术分析新鲜全血、激活诱导标记法检测抗原特异性CD4 T细胞、刺突探针研究抗原特异性B细胞。

主要发现

  • 接种两剂SARS-CoV-2疫苗后7天,甲氨蝶呤治疗患者与对照的总B细胞和T细胞计数相似。
  • 刺突特异性B细胞频率未受影响。
  • 甲氨蝶呤治疗患者抗原特异性CD4 T细胞频率降低,并与抗RBD IgG抗体强相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This raises concerns about the vulnerability of these patients to emerging infections and following vaccination. METHODS: In the current study, we investigated the impact of MTX treatment in patients with immune-mediated inflammatory disease on B and CD4 T cell SARS-CoV-2 vaccination responses. Eighteen patients with RA and two patients with psoriatic arthritis on MTX monotherapy were included, as well as 10 patients with RA without immunosuppressive treatment, and 29 healthy controls. CD4 T and B cell responses were analysed 7 days and 3-6 months after two SARS-CoV-2 messenger RNA vaccinations. High-dimensional flow cytometry analysis was used to analyse fresh whole blood, an activation-induced marker assay to measure antigen-specific CD4 T cells, and spike probes to study antigen-specific B cells. RESULTS: Seven days following two SARS-CoV-2 vaccinations, total B and T cell counts were similar between MTX-treated patients and controls. In addition, spike-specific B cell frequencies were unaffected. Remarkably, the frequency of antigen-specific CD4 T cells was reduced in patients using MTX and correlated strongly with anti-RBD IgG antibodies. These results suggest that decreased CD4 T cell activity may result in slower vaccination antibody responses in MTX-treated patients. CONCLUSION: Taken together, MTX treatment reduces vaccine-induced CD4 T cell activation, which correlates with lower antibody responses. TRIAL REGISTRATION NUMBER: NL8900.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kummer LYL, Fernández Blanco L, Kreher C, et al. Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID. RMD Open. 2024. PMID: 39375177. doi:10.1136/rmdopen-2024-004664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。